EUVIMEDEUVIMED entdecken
Open Access

Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears

Marissa K Grossman iD, Danielle A Rankin, Meghan Maloney, Richard A Stanton, Paige Gable, Valerie A Stevens, Thomas Ewing, Katharine Saunders, Sarah Kogut, Elizabeth Nazarian, Sandeep Bhaurla, Jehan Mephors und 14 weitere

Clinical Infectious Diseases · 19.07.2024 · 79 (1) · 6-14

DOI: 10.1093/cid/ciae052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 05.02.2024. Verfasst von Marissa K Grossman und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Disease Outbreaks, Pseudomonas aeruginosa, Pseudomonas Infections, Drug Resistance, Multiple, Bacterial. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS, Centers for Disease Control and Prevention (CDC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa (CP-CRPA) are extensively drug-resistant bacteria. We investigated the source of a multistate CP-CRPA outbreak.

Methods

Cases were defined as a US patient's first isolation of P. aeruginosa sequence type 1203 with carbapenemase gene blaVIM-80 and cephalosporinase gene blaGES-9 from any specimen source collected and reported to the Centers for Disease Control and Prevention during 1 January 2022–15 May 2023. We conducted a 1:1 matched case-control study at the post–acute care facility with the most cases, assessed exposures associated with case status for all case-patients, and tested products for bacterial contamination.

Results

We identified 81 case-patients from 18 states, 27 of whom were identified through surveillance cultures. Four (7%) of 54 case-patients with clinical cultures died within 30 days of culture collection, and 4 (22%) of 18 with eye infections underwent enucleation. In the case-control study, case-patients had increased odds of receiving artificial tears versus controls (crude matched OR, 5.0; 95% CI, 1.1–22.8). Overall, artificial tears use was reported by 61 (87%) of 70 case-patients with information; 43 (77%) of 56 case-patients with brand information reported use of Brand A, an imported, preservative-free, over-the-counter (OTC) product. Bacteria isolated from opened and unopened bottles of Brand A were genetically related to patient isolates. Food and Drug Administration inspection of the manufacturing plant identified likely sources of contamination.

Conclusions

A manufactured medical product serving as the vehicle for carbapenemase-producing organisms is unprecedented in the United States. The clinical impacts from this outbreak underscore the need for improved requirements for US OTC product importers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease OutbreaksPseudomonas aeruginosaPseudomonas InfectionsDrug Resistance, Multiple, BacterialBacterial Proteinsbeta-LactamasesHumansCase-Control StudiesMaleFemaleMiddle AgedAgedUnited StatesAdultAnti-Bacterial AgentsAged, 80 and overMicrobial Sensitivity TestsYoung AdultCephalosporinaseCarbapenems

Stichwörter der Autor:innen

artificial tearscarbapenem resistancedrug-resistant Pseudomonasmultistate outbreakother-the-counter medications

Substanzen

Bacterial Proteinscarbapenemasebeta-LactamasesAnti-Bacterial AgentsCephalosporinaseCarbapenems

Autor:innen und Institutionen

  • Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Connecticut Department of Public Health, Hartford, Connecticut, USA.
  • Florida Department of Health, Tallahassee, Florida, USA.
  • New York State Department of Health, Albany, New York, USA.
  • New York State Department of Health, Wadsworth Center, Albany, New York, USA.

ORCID-Profile: Marissa K Grossman

Förderung

  • Intramural CDC HHS
  • Centers for Disease Control and Prevention (CDC)

Zitieren

APA

Grossman, M. K., Rankin, D. A., Maloney, M., Stanton, R. A., Gable, P., Stevens, V. A., Ewing, T., Saunders, K., Kogut, S., Nazarian, E., Bhaurla, S., Mephors, J., Mongillo, J., Stonehocker, S., Prignano, J., Valencia, N., Charles, A., McNamara, K., Fritsch, W. A., …, & Multistate Pseudomonas Outbreak Investigation Group (2024). Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears. Clinical Infectious Diseases, 79(1), 6-14. https://doi.org/10.1093/cid/ciae052

Vancouver

Grossman MK, Rankin DA, Maloney M, Stanton RA, Gable P, Stevens VA, et al. Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears. Clinical Infectious Diseases. 2024;79(1):6-14. doi:10.1093/cid/ciae052

BibTeX
@article{Grossman2024,
  author = {Grossman, Marissa K and Rankin, Danielle A and Maloney, Meghan and Stanton, Richard A and Gable, Paige and Stevens, Valerie A and Ewing, Thomas and Saunders, Katharine and Kogut, Sarah and Nazarian, Elizabeth and Bhaurla, Sandeep and Mephors, Jehan and Mongillo, Joshua and Stonehocker, Susan and Prignano, Jeanette and Valencia, Nickolas and Charles, Argentina and McNamara, Kiara and Fritsch, William A and Ruelle, Shannon and Plucinski, Carrie Ann and Sosa, Lynn E and Ostrowsky, Belinda and Ham, D Cal and Walters, Maroya S and Multistate Pseudomonas Outbreak Investigation Group, Multistate Pseudomonas Outbreak Investigation Group},
  title = {Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {79},
  number = {1},
  pages = {6--14},
  doi = {10.1093/cid/ciae052}
}
Kostenlos starten →